Successful rapid desensitization for cetuximab-induced anaphylaxis
Allergy, Asthma & Respiratory Disease
;
: 294-296, 2015.
Artigo
em Coreano
| WPRIM
| ID: wpr-83768
ABSTRACT
Cetuximab, a chimeric mouse-human immunoglobulin, is an antiepidermal growth factor receptor monoclonal antibody. It has been approved by the U.S. Food and Drug Administration for the treatment of metastatic colorectal and head/neck cancer, but can cause fatal hypersensitivity reactions in some patients. A 66-year-old male with metastatic sigmoid cancer had cetuximab-induced anaphylaxis when the first dose of cetuximab was administered. Cetuximab was safely readministered for another 15 cycles based on the rapid desensitization protocol. We experienced a case of cetuximab-induced anaphylaxis on the first exposure which was successfully managed by rapid desensitization.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Neoplasias do Colo Sigmoide
/
United States Food and Drug Administration
/
Imunoglobulinas
/
Dessensibilização Imunológica
/
Cetuximab
/
Hipersensibilidade
/
Anafilaxia
Tipo de estudo:
Guia de Prática Clínica
Limite:
Idoso
/
Humanos
/
Masculino
Idioma:
Coreano
Revista:
Allergy, Asthma & Respiratory Disease
Ano de publicação:
2015
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS